{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Oragenics Inc."},"Symbol":{"label":"Symbol","value":"OGEN"},"Address":{"label":"Address","value":"4902 EISENHOWER BOULEVARD,SUITE 125, TAMPA, Florida, 33634, United States"},"Phone":{"label":"Phone","value":"+1 813 286-7900"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious diseases and on developing effective treatments for oral mucositis. Oragenics involves developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and having other product candidates, including SMaRT Replacement Therapy positioned for out-licensing or partnering. It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus."},"CompanyUrl":{"label":"Company Url","value":"https://www.oragenics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"James Kelly","title":"Chief Medical Officer"},{"name":"Joseph Michael Redmond","title":"President & Chief Executive Officer"},{"name":"William M. Peacock","title":"Chief Clinical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}